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Abstract 
The squamous cell carcinoma antigen (SCCA) serves as a serological marker for 
squamous cell carcinomas.  Molecular cloning of the SCCA genomic region has revealed the 
presence of two tandemly arrayed genes, SCCA1 and SCCA2.  We examined the promoter 
activity of the 5’-flanking proximal region of the SCCA1 gene.  Deletion analysis of SCCA1 
promoter identified a 175-bp core promoter region and an enhancer region at -525 to -475 bp 
upstream of the transcription start site.  The transcriptional activity of the SCCA1 promoter was 
up-regulated in squamous cell carcinoma cells, compared with normal keratinocyte, normal non-
keratinocyte and adenocarcinoma cells.  Five tandem repeats of enhancer increased SCCA1 
promoter activity by 4-fold.  Oncolytic adenovirus driven by the SCCA1 promoter with 5 tandem 
repeats of enhancer specifically killed squamous cell carcinoma cells in vitro and in vivo.  A549 
carrier cells infected with the oncolytic adenovirus induced complete regression of tumor by 
overcoming immunogenicity and adenovirus-mGM-CSF augmented the antitumor effect of 
carrier cells.  These findings suggest that SCCA1 promoter is a potential target of gene therapy 
for squamous cell carcinoma. 
 3
Introduction 
Squamous cell carcinoma antigen (SCCA) is a circulating tumor marker for squamous 
cell carcinoma, especially that of cervix, head and neck, lung, and esophagus.1  Elevated 
circulating levels of SCCA are not detected in patients with adenocarcinomas of the uterus, 
ovary, or breast.2  Several studies have shown that increased serum SCCA levels are correlated 
with extent of disease in patients with squamous cell carcinoma.2-4  Higher SCCA levels are also 
indicative of deep tumor infiltration and lymph node involvement.5, 6  Moreover, measurement of 
post-treatment SCCA levels is useful for monitoring the response to therapy and for predicting 
tumor recurrence and metastasis.  SCCA protein has been isolated from a metastatic, cervical 
squamous cell carcinoma.2  Molecular cloning of the SCCA genomic region revealed the 
presence of two tandemly arrayed genes, SCCA1 and SCCA2.  Although SCCA1 and SCCA2 are 
nearly identical members of the serpin superfamily, the significant differences in their reactive 
site loops suggest that SCCA1 is a papain-like cysteine proteinase inhibitor, while SCCA2 is a 
chymotrypsin-like serine proteinase inhibitor.7   
Previous studies have reported the cloning and characterization of the promoter region of 
SCCA18 and SCCA2.9  SCCA1 gene expression and promoter activity is up-regulated in 
squamous cell carcinoma cells, compared with keratinocyte and adenocarcinoma cells.8, 10  
SCCA2 gene expression and promoter activity are also increased in squamous cell carcinoma 
cells compared with normal and adenocarcinoma cells, though the SCCA1 gene expression and 
promoter activity are higher than the SCCA2 gene expression in almost all squamous carcinoma 
cells and tissues.8, 10  These findings suggest that SCCA1 promoter may be a potential target of 
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gene therapy for squamous cell carcinoma.  Although the SCCA2 promoter has been introduced 
into E1-deleted adenovirus to transduce an apoptotic gene in lung cancer11, use of SCCA1 
promoter-driven adenovirus to treat squamous cell carcinoma has not yet been reported.  We 
found that up to 5 consecutive tandem-repeat enhancer elements significantly increased SCCA1 
promoter activity.  Oncolytic adenovirus AdE3-SCCA1 was constructed by replacement of 
adenovirus E1A promoter with this tandem-repeat enhancer and promoter complex and 
specifically killed squamous cell carcinoma cells.   
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Results 
 Expression of SCCA protein  
To determine the levels of expression of SCCA protein in human cervical squamous cell 
carcinoma cells, ELISA was performed in the medium of each cell line.  SKGIIIa and HT-III 
cells secreted the highest concentrations of SCCA proteins into medium (Fig. 1).  The mean 
SCCA protein level secreted by cervical squamous cell carcinoma cells was 15 times that by 
keratinocyte cells, 404 times that by normal non-keratinocyte cells, and 329 times that by 
adenocarcinoma cells.  The mean SCCA protein level secreted by keratinocyte cells was 28 
times that by normal non-keratinocyte cells, and 23 times that by adenocarcinoma cells.  The 
mean SCCA protein level secreted by normal non-keratinocyte cells was not significantly 
different from that by adenocarcinoma cells.   
 
 mRNA levels of SCCA1 and SCCA2 in cervical squamous cell carcinoma cells 
 To examine the mRNA levels of SCCA1 and SCCA2 in cervical squamous cell carcinoma 
cells, one-step real time RT-PCR was performed using MGB probe.  The mRNA level of SCCA1 
was one or two order of magnitude higher than that of SCCA2 in all cell types examined (Fig. 2).  
The mRNA level of SCCA1 in cervical squamous cell carcinoma cells was 8.5, 280, and 195 
times those in normal keratinocyte, normal non-keratinocyte, and adenocarcinoma cells, 
respectively.  The mRNA level of SCCA1 in normal keratinocyte cells was 33 and 23 times those 
in normal non-keratinocyte and adenocarcinoma cells, respectively.  The mRNA level of SCCA1 
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in normal non-keratinocyte cells was not significantly different from that in adenocarcinoma 
cells.    
 
 Transcriptional activities of SCCA1 and SCCA2 in squamous cell carcinoma cells 
 To examine the transcriptional activities of SCCA1 in squamous cell carcinoma cells, 
transient expression assays were performed.  Luciferase reporter plasmids containing varying 
lengths of the 5’-flanking regions of the gene were constructed (SCCA1-750, SCCA1-550, 
SCCA1-525, SCCA1-500, SCCA1-475, SCCA1-450, SCCA1-375, SCCA1-250, SCCA1-175, 
SCCA1-125, and SCCA1-75) as shown in Fig. 3a and transfected into HT-III cells, and cell 
lysates were tested in luciferase assays.  Fig. 3b demonstrates the transcriptional activities in 
HT-III cells.  Deletion analysis from the -750-bp to -525-bp region upstream from the gene 
revealed gradual increase in transcriptional activity with decrease in length, suggesting the 
presence of a sequence inhibiting transcriptional activities of the gene between -750-bp and -
525-bp.  A region from -525-bp to -475-bp of the SCCA1 promoter demonstrated significant 
transcriptional activity.  Deletion analysis from the -450-bp to -175-bp region upstream from the 
gene revealed gradual increase in transcriptional activity with decrease in length of promoter, 
suggesting the presence of a sequence inhibiting transcriptional activities of the gene between -
450-bp and -250-bp.  A -175-bp region of SCCA1 promoter demonstrated significant 
transcriptional activity.  This proximal negative region from -525-bp to -475-bp and positive -
175-bp region have not reported previously.8 
 7
 To determine the enhancer region, the intron 1 region or proximal promoter region from -
525-bp to -475-bp was inserted into upstream of the -175-bp region of SCCA1 luciferase 
promoter plasmid.  Luciferase reporter plasmids of SCCA1-175 containing intron 1 in sense or 
antisense orientation or the region from -525-bp to -475-bp were constructed (INT-SCCA1-175 
for sense orientation of intron 1, INT-AS-SCCA1-175 for antisense orientation of intron 1, 525-
SCCA1-175 for sense orientation of -525-bp to -475-bp , 525-AS-SCCA1-175 for antisense 
orientation of -525-bp to -475-bp, 525x2-SCCA1-175, 525x3-SCCA1-175, 525x4-SCCA1-175, 
525x5-SCCA1-175, 525x10-SCCA1-175, and 525x20-SCCA1-175 for tandem repeats of -525-
bp to -475-bp) as shown in Fig. 4a and transfected into HT-III cells, and cell lysates were tested 
in luciferase assays.  Fig. 4b demonstrates the transcriptional activities in HT-III cells.  Intron 1 
did not enhance SCCA1-175 promoter activity, consistent with a previous report.13  However, 
the sense and antisense orientations of the -525-bp to -475-bp region significantly enhanced 
SCCA1-175 promoter activity, indicating that this region functioned as an enhancer for the 
SCCA1-175 promoter.  Five tandem repeats of the -525-bp to -475-bp region increased SCCA1-
175 promoter activity up to four-fold, while 10 or 20 tandem repeats of this enhancer region did 
not further increase SCCA1-175 promoter activity compared with 5 tandem repeats.   
 To compare the tissue specificity of the transcriptional activity of enhancer-promoter 
complex of SCCA1 promoter, various numbers of tandem repeats of enhancer and SCCA1-175 
promoters were transfected into HT-III squamous cell carcinoma cells and H1299 
adenocarcinoma cells.  The promoter activity of SCCA1-175 in HT-III cells was 20 times that in 
H1299 cells and the promoter activity of 5 tandem repeats of the enhancer and SCCA1-175 in 
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HT-III cells was 37 times that in H1299 cells (Fig. 4c).  Thus, 5 tandem repeats of enhancer and 
promoter complex exhibited significant tissue specificity in squamous cell carcinoma cells 
compared with adenocarcinoma cells. 
 To compare the tissue specificity of transcriptional activity of the enhancer-promoter 
complex of SCCA1 promoter, SCCA1-175 with 5 tandem repeats of enhancer and SCCA1-175 
promoter were transfected into squamous cell carcinoma cells, normal keratinocyte, normal non-
keratinocyte cells, and adenocarcinoma cells.  The promoter activity of SCCA1-175 in squamous 
cell carcinoma cells was 2.4 times that in keratinocyte cells, 7.6 times that in normal non-
keratinocyte cells, and 13 times that in adenocarcinoma cells (Fig. 4d).  The promoter activity of 
SCCA1-175 in normal keratinocytes was 3 times that in non-keratinocyte cells, and 5 times that 
in adenocarcinoma cells.  The promoter activity of 5 tandem repeats of enhancer and SCCA1-
175 in squamous cell carcinoma cells was 5 times that in keratinocytes, 16 times that in non-
keratinocyte cells, and 30 times that in adenocarcinoma cells.  The promoter activity of 5 tandem 
repeats of enhancer and SCCA1-175 in keratinocytes was 3 times that in non-keratinocyte cells, 
and 6 times that in adenocarcinoma cells.  The promoter activities of SCCA1-175 and SCCA1-
175 with tandem repeats of enhancer did not differ significantly between normal non-
keratinocyte cells and adenocarcinoma cells.  Thus, 5 tandem repeats of enhancer significantly 
increased SCCA1-175 promoter activity in squamous cell carcinoma cells compared with normal 
keratinocytes, normal non-keratinocyte cells, and adenocarcinoma cells.   
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Transcriptionally targeted AdE3-SCCA1 has a potent antiproliferative effect in 
squamous cell carcinoma cells but not in normal non-keratinocyte cells or adenocarcinoma 
cells 
To estimate the potential of SCCA1 promoter for use in gene therapy for squamous cell 
carcinoma, SCCA1 promoter-driven oncolytic adenovirus was constructed and transfected into 
each cell line.  Fig. 5a shows the construct of oncolytic adenovirus AdE3-SCCA1 in which the 
404-551bp region of E1A promoter was substituted by 5 tandem repeats of enhancer and 
SCCA1-175 promoter complex.   Fig. 5b shows the growth-inhibitory effects (IC50) of oncolytic 
adenovirus AdE3-SCCA1 in various types of cell lines.  The IC50 of wild-type adenovirus AdE3 
did not differ significantly among squamous cell carcinoma cells, normal keratinocytes, normal 
non-keratinocyte cells nor adenocarcinoma cells.  AdE3-SCCA1 killed neither normal non-
keratinocyte cells nor adenocarcinoma cells.  AdE3-SCCA1 significantly suppressed the growth 
of normal keratinocytes compared with normal non-keratinocyte cells and adenocarcinoma cells.   
Furthermore, this growth-inhibitory effect of AdE3-SCCA1 was significantly enhanced in 
squamous cell carcinoma cells, and was one or two orders of magnitude higher than in normal 
keratinocytes.   
 
Oncolytic adenovirus AdE3-SCCA1 suppresses subcutaneous tumor growth of 
squamous cell carcinoma in nude and syngeneic mice   
To evaluate the antitumor effect of AdE3-SCCA1, xenograftic subcutaneous tumors were 
established in the flanks of nude mice using cervical cancer HT-III and adenocarcinoma H1299 
cells.  By 30 days, we observed significant reduction in tumor size in the AdE3-SCCA1- and 
AdE3-treated groups compared with the medium alone- and Ad5CMV-LacZ-treated groups in 
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the HT-III tumor models.  AdE3-SCCA1 and AdE3 significantly reduced tumor sizes by 95-98% 
compared with medium alone and Ad5CMV-LacZ (P < 0.001, unpaired t-test) (Fig. 6a).  In 
contrast, AdE3-SCCA1 did not significantly reduce the sizes of H1299 tumors compared with 
Ad5CMV-LacZ (Fig. 6b).  However, AdE3 significantly reduced the size of H1299 tumors by 
96% compared with Ad5CMV-LacZ (P < 0.001, unpaired t-test).   
To evaluate the antitumor effects of AdE3-SCCA1 after immunization, C3H mice were 
immunized with Ad5CMV-LacZ and subcutaneous tumors 5-8 mm in diameter were established 
in the left thigh of C3H mice using mouse squamous carcinoma SCC7 cells (Fig. 6c).  Survival 
of control mice was not significantly different from that of the mice treated with AdE3-SCCA1 
alone.  Survival of mice treated with A549 carrier cells infected with AdE3-SCCA1 was 
significantly longer than those of the mice treated with medium control or AdE3-SCCA1.  
Furthermore, simultaneous infection with AxCAmGM-CSF augmented the antitumor effect of 
A549 carrier cells infected with AdE3-SCCA1 (P < 0.05).  Mice that exhibited complete tumor 
regression were resistant to subsequent inoculation of SCC7 cells. 
 
 11
Discussion 
In the present study, the highest SCCA1 promoter activities were found in the 175-bp 
region just upstream of the SCCA1 gene.  It has been reported that a 0.5-kb fragment upstream of 
the SCCA1 gene exhibited significant promoter activity.8  This is consistent with the enhancer 
region and promoter activity identified in the present study.  The negative element in the region 
0.3- to 0.4-kb upstream of the SCCA1 gene was reported previously,12 and corresponds to the 
negative 250- to 450-bp region in the present study.  The positive 175-bp SCCA1 promoter 
element had not yet been previously reported because the promoter activity of the 0- to 200-bp 
fragment of the SCCA1 gene remained to be determined.  The present study is thus the first to 
report promoter analysis of the proximal region of SCCA1 promoter and determine the maximal 
promoter activity of the 175-bp fragment of the SCCA1 gene.  
This study also revealed an enhancer region 475-bp to 525-bp upstream of SCCA1.  It has 
been reported that intron 1 in sense orientation alone increased 0.3-kb SCCA1 promoter activity 
by 2-fold, while that in antisense orientation did not increase it.12  However, intron 1 in neither 
sense nor antisense orientation increased SCCA1 promoter activity in the present study, 
suggesting that intron 1 is not a major enhancer of SCCA1.  In stead, we found that the 475-bp to 
525-bp fragment increased SCCA1-175 promoter activity by 50% in sense and antisense 
orientations.  The 475-bp to 525-bp fragment thus appears to be a major enhancer region of 
SCCA1.  The double and triple enhancers further increased promoter activity compared with the 
single enhancer in this study.  Use of 5 tandem repeats of minimum enhancer element increased 
promoter activity the most, by 4 times, compared with 1 to 4, 10, or 20 tandem repeats of the 
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enhancer element.  Thus, 5 tandem repeats of minimum enhancer element significantly increased 
the promoter activity, and thus might enhance the amplification and the anti-tumor effect of 
replication-competent adenovirus.  
SCCA protein, SCCA1 mRNA, and SCCA2 mRNA levels and SCCA1-175 promoter 
activity in squamous cell carcinoma cells were significantly higher than those in normal 
keratinocytes, which were in turn significantly higher than those in normal non-keratinocyte and 
adenocarcinoma cells.  Although comparisons of SCCA gene expression and promoter activity 
among squamous cell carcinoma cells, normal keratinocytes and adenocarcinoma cells were 
reported previously,8, 10 comparisons among squamous cell carcinoma cells, normal 
keratinocytes and normal non-keratinocyte cells had not previously performed.  SCCA1-175 and 
525x5-SCCA1-175 promoter activities in normal keratinocytes were significantly higher than 
those in normal non-keratinocyte cells, and oncolytic adenovirus AdE3-SCCA1 significantly 
suppressed in vitro growth of normal keratinocyte cells compared with that of normal non-
keratinocyte cells.  These findings suggest that the SCCA1 promoter might also be useful for 
gene therapy for skin disease other than cancer.   
The SCCA1 to SCCA2 mRNA ratio in squamous cell carcinoma cells was significantly 
decreased compared with that in the other cells examined, since the relative increase in SCCA2 
mRNA was significantly higher than that in SCCA1 mRNA in squamous cell carcinoma cells 
compared with other cells.  The adenovirus-mediated SCCA2 promoter-driven proapoptotic gene 
thus induced selective tumor suppression of squamous cell carcinoma cells compared with 
adenocarcinoma cells11 though this effect was not sufficient to induce complete tumor 
 13
regression, since SCCA1 promoter activity is higher than SCCA2 promoter activity in squamous 
cell carcinoma cells.  We therefore used the SCCA1 promoter for gene therapy for squamous cell 
carcinoma cells.  Furthermore, although SCCA1 promoter alone was not sufficient for 
overexpression of genes, 5 tandem repeats of enhancer increased SCCA1 promoter activity by 4-
fold and increased the selectivity for squamous cell carcinoma by 2-fold compared with that for 
other cells examined.    
Oncolytic adenovirus AdE3-SCCA1 selectively killed squamous cell carcinoma cells in 
vitro and in vivo.  Squamous cell carcinoma can occur in many different organs, including the 
skin, lips, mouth, esophagus, urinary bladder, prostate, lungs, vagina, cervix, and others.  
Although oncolytic adenovirus vector driven by SCCA2 promoter11 has been reported, SCCA1 
promoter-driven oncolytic virotherapy has not been.  The present study is the first report of 
SCCA1-specific gene therapy.  In clinical trials for squamous cell carcinoma, although 
adenovirus-p53 for head and neck cancer,14 lung cancer15 and esophageal cancer,16 and 
replicative oncolytic adenovirus for head and neck caner17 have been reported, the results of  
such clinical trials were clinically insufficient, since adenoviral infection was completely 
blocked by the production of anti-adenovirus antibody.  This finding is identical to those for 
gene therapy with other viruses.  It has been reported that oncolytic virus-infected carrier cells 
overcome the viral induced humoral immune response, the viral induced cellular immune 
response kills virus-infected target cancer cells, and GM-CSF augments the antitumor effect of 
carrier cells.18  The present study also demonstrated that oncolytic adenovirus-infected A549 
carrier cells induced elimination of tumor and adenovirus-GM-CSF augmented the antitumor 
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effect of carrier cells, which induced complete regression of tumor in 90% of mice.  
Furthermore, second challenge of syngeneic mouse squamous cell carcinoma was completely 
rejected by a specific anti-tumor response, also suggesting that the systemic tumor immune 
response induced by carrier cell treatment may cure not only the carrier cells-injected local 
tumor but also the non-injected metastatic tumor.  In conclusion, SCCA1 promoter-driven 
oncolytic adenovirus-infected carrier cells may cure human squamous cell carcinoma of the head 
and neck, skin, esophagus, lung, cervix, and other organs and human clinical trials by these 
squamous cell carcinoma-specific carrier cells should be possible in the near future.   
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Materials and methods 
Cell lines and culture conditions   
Human non-small cell lung cancer A549, cervical squamous cell carcinoma SKGIIIa and 
gastric cancer AGS cells were obtained from the Japanese Collection of Research Bioresources 
Cell Bank (Osaka, Japan).  Human ovarian carcinoma HEY and 2774 cells from Dr. G. Mills, 
murine squamous cell carcinoma SCC7 cells from Dr. L. Milas, and human non-small cell lung 
cancer H1299 cells from Dr. J. A. Roth were obtained (The University of Texas, M.D. Anderson 
Cancer Center, TX).  Normal human keratinocyte SV, HPK, NHK and K42 cells and normal 
human fibroblast F27 cells were established by Dr. K. Hashimoto, Ehime University, Japan.  
Normal human fibroblast NF and ovarian fibroblast NOE cells were established in our 
laboratory.  Human umbilical vein endothelial HUVEC cells was obtained from Cambrex Bio 
Science Walkersville Inc. (Walkersville, MD).  Human cervical squamous cell carcinoma HT-
III, C4I, C4II, and CaSki cells, and human cervical adenocarcinoma HeLa cells were obtained 
from the American Type Culture Collection (Rockville, MD).   
Cells were maintained in a humidified 5% CO2/95% air incubator at 37°C.  All cell lines 
except NHK, K42, and HUVEC cells were grown in RPMI medium supplemented with 10% 
heat-inactivated fetal bovine serum.  NHK and K42 cells were grown in MCDB153 (Nissui Co., 
Tokyo, Japan) with bovine hypothalamus extract.  HUVEC cells was grown in EBM-2 
(Cambrex, MD) 
 
Construction of the AdE3-SCCA1 vector   
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The pXC1 plasmid has adenovirus 5 sequences from nt 22 to nt 5790 containing the E1 
gene (Microbix Biosystems Inc., Toronto, Canada).  A unique AgeI site was introduced at 
nucleotide position 404 after deletion between nt 404 and nt 552 to generate the plasmid pXC1-
404-AgeI.  The SCCA1 promoter was ligated to pXC1-404-AgeI plasmid to obtain pXC1-
SCCA1.  To construct the AdE3-SCCA1 virus, homologous recombination was performed 
between pXC1-SCCA1 plasmid and the right hand side of pBHGE3 adenovirus DNA containing 
the E3 region in 293 cells by a standard technique.19  To construct the wild type adenovirus 
AdE3, homologous recombination was performed between pXC1 and pBHGE3 in 293 cells.  
The replication defective E1-deleted Ad5CMV-LacZ virus was used as control adenovirus.  All 
viruses were purified with double Cesium Chloride gradients using standard methods, and titered 
with standard spectrophotometry and plaque assay.19  
  
 Enzyme-linked immunosorbent assay   
Each cell was seeded at 4 x 106 cells into 100 mm culture dishes and incubated for 2 days 
with 10 ml of culture medium.  Each cell line was cultured in triplicate dishes.  Supernatants 
were obtained from culture medium in each dish, centrifuged for 5 min at 3000 rpm at room 
temperature, and assayed to detect SCCA protein.  An enzyme-linked immunosorbent assay 
(ELISA) for SCCA (IMx SCC•DAINAPACKTM; Dainabot Co., Tokyo, Japan) was used to 
evaluate the concentrations of SCCA protein in medium.  Medium samples (2 ml) were 
concentrated ten-fold by centrifugation with a Centricon-10 (Millipore Corp., Bedford, MA).  
Concentrated samples (200 μl) were applied to an automatic assay apparatus (IMx analyzer; 
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Dainabot).  The lower limit of detection with this ELISA system was 0.01 ng/ml.  This assay 
system could detect both SCCA1 and SCCA2 proteins.  The mean values of samples were 
determined in triplicates.  All experiments were performed at least three times and gave similar 
results. 
 
Real-time quantitative RT-PCR   
One hundred ng RNA samples were used in RT and real-time PCR for RNA expression 
studies.  A reverse transcriptase and real-time PCR reaction was carried out with the ABI prism 
7700 sequence detection system (Applied Biosystems, Foster City, CA) in a total volume of 50 
μl that contained TaqMan one step RT-PCR master mix (Applied Biosystems), 0.3 μM of each 
forward and reverse primer, and 0.21 μM of MGB probe.  The forward and reverse primer and 
MGB probe were respectively 5’-CCACCGCTGTAGTAGGATTCG-3’, 5’-
GGAAAGGGTGATTACAATGGAACTC-3’ and 5’-ATCATCACCTACTTCAAC-3’ for 
SCCA1 and 5’-CATGACCTGGAGCCACGG-3’, 5’-CCCTCCTCAGTGACCTCCAC-3’ and 5’-
CTCTCAGTATCTAAAGTCCTAC-3’ for SCCA2.  The reaction was performed with the 
following thermal cycling method: 30 min at 48°C for reverse transcription, 5 min at 95°C for 
AmpliTaq Gold activation, 15s at 95°C and 60 s at 60°C for 40 cycles.  GAPDH was chosen as a 
housekeeping gene to be tested as an endogenous control. 
 
Assay for promoter activity   
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SCCA1 and SCCA2 promoter fragments were inserted into the luciferase reporter vector 
PicaGene Basic, a promoterless and enhancerless vector (Toyo Ink MFG Co., Tokyo, Japan).  
The sequence of each insert was confirmed by an ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems, Foster City, CA).  Constructs containing SCCA1 and SCCA2 promoter sequences 
were fused to the Luciferase gene which were transfected into cells in the presence of 
Lipofectamine transfection reagent (Invitrogen, Carisbad, CA), according to the protocol 
recommended by the manufacturer.  Briefly, 1 x 105 cells seeded in a 12-well culture dish were 
exposed to transfection mixtures containing 1 μg of luciferase reporter plasmids and 0.2 μg of 
prenilla luciferase-herpes simplex virus thymidine kinase promoter control vector (Promega, 
Madison, WI) at 37°C for 48 h.  Dual luciferase assays were performed according to the 
manufacturer’s protocol (Promega). 
 
Cell count assay   
Cells were plated at a density of 5 x 103 cells/well in 12-well plates.  Cells were infected 
with AdE3-SCCA1 or AdE3.  Culture medium alone was used as a mock infection control.  After 
15 days, cells were harvested and counted to determine the 50% growth inhibitory concentration 
(IC50).   
 
 Inhibition of subcutaneous tumor growth in vivo   
To determine inhibition of xenograftic subcutaneous tumor growth, AdE3-SCCA1 was 
injected into subcutaneous tumors in female nude (nu/nu) mice (CLEA Japan Inc., Tokyo, 
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Japan).  In brief, 1 x 107 HT-III or H1299 cells in 100 µl of RPMI were injected into the left 
posterior flank of each mouse through an insulin syringe with a 27 1/2-gauge needle.  Ten 
animals were used for each group.  After 25 days, tumors with a diameter of 5 to 8 mm were 
established.  Then 100 μl of AdE3 (1 x 1010 PFU), AdE3-SCCA1 (1 x 1010 PFU), Ad5CMV-
LacZ (1 x 1010 PFU), or medium alone was injected intratumorally on days 0, 1, 2, 3, 4, and 5.  
The tumors were measured every 5 days with calipers in two perpendicular diameters.  Tumor 
volume was calculated by assuming a spherical shape, with the average tumor diameter 
calculated as the square root of the product of cross-sectional diameters.   
To determine inhibition of syngeneic subcutaneous tumor growth, murine SCC7 cells (1 
x 106) were injected into the left posterior flank of female C3H mice (CLEA) and AdE3-SCCA1 
was injected into subcutaneous tumors.  Ten animals were used for each group.  Medium alone, 
AdE3-SCCA1 (1 x 1010 PFU), or A549 carrier cells (5 x 106) infected with AdE3-SCCA1 at 200 
MOI and A549 carrier cells (5 x 106) infected with AdE3-SCCA1 at 200 MOI and AxCAmGM-
CSF at 10 MOI were injected into the tumors 5 to 8 mm in diameter on days 0, 1, and 2.  Mice 
were preimmunized with Ad-LacZ (1 x 1010 PFU) on day -21.   
Animal studies have been approved by the Ehime University Review Board. 
 
Statistical analysis   
Values are the mean ± S.D., and were examined with the unpaired t-test, Welch test, and 
regression analysis.  Survival data were plotted on Kaplan-Meier curves, and examined with the 
log-rank test using the LIFETEST procedure.  Findings of P < 0.05 were considered significant.   
 20
 
Acknowledgements  
This study was supported by a grant from the Ministry of Education, Science, Sports and 
Culture, Japan and by the Integrated Center for Science, Ehime University.  We thank K. Oka for 
preparing culture medium and S. Hirose for comments and discussion.  The authors have no 
conflicting financial interests. 
 21
 References  
 
1. Takeshima N, Suminami Y, Takeda O, Abe H, Okuno N, Kato H.  Expression of mRNA of 
SCC antigen in squamous cells.  Tumor Biol  1992; 13: 338-342. 
2. Kato H, Torigoe H.  Radioimmunoassay for tumor antigen of human cervical squamous cell 
carcinoma.  Cancer  1977; 40: 1621-1628. 
3. Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL.  An evaluation of 
squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma.  Am J 
Obstet Gynecol  1987; 157:  433-439. 
4. Bolli JA, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K et al.  Squamous cell 
carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.  
Gynecol Oncol  1994; 55: 169-173. 
5. Duk JM, de Bruijn HXA, Groenier KH, Hollema H, ten Hoor KA, Krans M et al.  Cancer of 
the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen 
determinations.  Gynecol Oncol  1990; 39: 186-194. 
6. Takeshima N, Hirai Y, Katase K, Yano K, Yamauchi K, Hasumi K.  The value of squamous 
cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer.  Gynecol Oncol  
1998; 68: 263-266. 
7. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD et al.  A serine proteinase 
inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell 
carcinoma antigen gene.  Proc Natl Acad Sci USA  1995; 92: 3147-3151. 
 22
 8. Hamada K, Shinomiya H, Asano Y, Kihana T, Iwamoto M, Hanakawa Y et al. 
Molecular cloning of human squamous cell carcinoma antigen 1 gene and 
characterization of its promoter.  Biochim Biophys Acta  2001; 91522:  1-8. 
9. Sakaguchi Y, Kishi F, Murakami A, Suminami Y, Kato H.  Structural analysis of human 
SCC antigen 2 promoter.  Biochim Biophys Acta  1999; 1444: 111-116. 
10. Hamada K, Hanakawa Y, Hashimoto K, Iwamoto M, Kihana T, Hirose S et al.  Gene 
expression of human squamous cell carcinoma antigens 1 and 2 in human cell lines.   
Oncol Rep 2001; 8: 347-54. 
11.  Hsu KF, Wu CL, Huang SC, Hsieh JL, Huang YS, Chen YF et al.  Conditionally replicating 
E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for 
uterine cervical cancer therapy.  Cancer Gene Ther 2008; 15: 526-34. 
12. Suminami Y, Kishi F, Nawata S, Murakami A, Sakaguchi Y, Sueoka K et al. Promoter 
analyses of SCC antigen genes.  Biochim Biophys  Acta  2005; 1727: 208-212. 
13. Latham JPF, Searle PF, Mautner V, James ND.  Prostate-specific antigen 
promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a 
tissue-specific adenovirus vector.  Cancer Res 2000; 60: 334-341.     
14. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA et al.  
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck 
squamous cell carcinoma.  J Clin Oncol 1998; 16: 2231-2232 . 
15. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T et al.  Multicenter phase I 
study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non–
 23
small-cell lung cancer.  J Clin Oncol 2006; 24: 1689-1699. 
16. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S et al.  Phase I/II 
adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous 
cell carcinoma.  Cancer Sci 2006; 97: 554-561. 
17. Nemunaitis J,  Khuri F,  Ganly I,  Arseneau J, Posner M, Vokes E et al.  Phase II trial of 
intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients 
with refractory Head and Neck cancer.  J Clin Oncol 2001; 19: 289-298. 
18. Hamada K, Desaki J, Nakagawa K, Shirakawa T, Gotoh A, Tagawa M.  Carrier cell-
mediated infection of a replication-competent adenovirus for cancer gene therapy.  Mol 
Ther 2007; 15: 1121-1128. 
19.  Hamada K, Kohno S, Iwamoto M, Yokota H, Okada M, Tagawa M et al.  Identification of 
the human IAI.3B promoter element and its use in the construction of a replication-selective 
adenovirus for ovarian cancer therapy.  Cancer Res 2003; 63: 2506-2512.   
 
 24
Figures 
 
Figure 1.  SCCA protein levels determined by ELISA in cervical squamous cell carcinoma, 
normal keratinocyte, normal non-keratinocyte and adenocarcinoma cells.  
 
Figure 2.  SCCA1 and SCCA2 mRNA levels determined by real time RT-PCR in cervical 
squamous cell carcinoma, normal keratinocyte, normal non-keratinocyte and 
adenocarcinoma cells. 
 
Figure 3.  (a), A schematic representation of SCCA1 reporter plasmids.  5’-truncated 
fragments of the promoter region upstream from the SCCA1 gene were inserted into 
luciferase (LUC) reporter vector in sense orientation.  Arrow indicates the transcription start 
site.  Numbers indicate the number of bases upstream (-) or downstream (+) from the 
transcription start site.  The name of each reporter construct was assigned according to the 
5’-end nucleotide numbers of inserted promoter sequences, upstream of the transcription start 
site.  (b), Transcriptional activity of SCCA1 promoter in HT-III cell line, and identification of 
core promoter region.  Bars, SD.  
 
Figure 4.  (a), A schematic representation of SCCA1 reporter plasmids with tandem repeats 
of enhancer region.  The intron 1 region or proximal promoter region from -525-bp to -475-
bp in sense or antisense orientation was inserted into upstream of the 175-bp region of 
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SCCA1 luciferase promoter plasmid.  Tandem repeats of proximal promoter region from -
525-bp to -475-bp were inserted into upstream of the 175-bp region of SCCA1 luciferase 
promoter plasmid.  (b), Luciferase activity of each reporter plasmid was examined in cervical 
squamous cell carcinoma HT-III.  The plasmid (pGV-control) driven by SV40 
enhancer/promoter was used as a positive control and pGV-Basic without enhancer/promoter 
as a negative control.  Bars, SD.  (c), Luciferase activity of each reporter plasmid was 
examined in cervical squamous cell carcinoma HT-III and adenocarcinoma H1299 cells.  The 
plasmid (pGV-control) driven by SV40 enhancer/promoter was used as a positive control and 
pGV-Basic without enhancer/promoter as a negative control.  Luciferase activity in each 
plasmid was plotted as the ratio to the positive control plasmid (pGV-control).  Bars, SD.  
(d), Luciferase activities of reporter plasmids SCCA1-175 and SCCA1-175 inserted with 5 
tandem repeats from -525 to -475 bp were examined in cervical squamous cell carcinoma, 
normal keratinocyte, normal non-keratinocyte and adenocarcinoma cells.  The plasmid 
(pGV-control) driven by SV40 enhancer/promoter was used as a positive control and 
luciferase activity in each cell line was plotted as the ratio to the positive control plasmid.  
Bars, SD.   
 
Figure 5.  (a), A schematic representation of oncolytic adenovirus AdE3-SCCA1.  SCCA1-
175 with 5 tandem repeats from -525 to -475 bp was replaced with 404 to 551 bp of E1A 
promoter region.  (b), The growth-inhibitory effects (IC50) of oncolytic adenovirus AdE3-
 26
SCCA1 and wild-type adenovirus AdE3 in cervical squamous cell carcinoma, normal 
keratinocyte, normal non-keratinocyte and adenocarcinoma cell lines.  Bars, SD. 
 
Figure 6.  (a), The antitumor effect of AdE3-SCCA1 in subcutaneous cervical squamous cell 
carcinoma HT-III cell tumors in nude mice.  (b), The antitumor effect of AdE3-SCCA1 
against subcutaneous adenocarcinoma H1299 cell tumors in nude mice.  (c), The antitumor 
effects of AdE3-SCCA1 against subcutaneous SCC7 tumors established in C3H mice after 
immunization.  RPMI medium, AdE3-SCCA1, A549 carrier cells infected with AdE3-
SCCA1, and A549 carrier cells infected with AdE3-SCCA1 and AxCAmGM-CSF were 
injected into each tumor.    
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